A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol
mBio · 2026
DOI: 10.1128/mbio.03518-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2026. Verfasst von Akito Kawai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Japan. Hauptthemen laut MEDLINE: Cephalosporins, Acinetobacter baumannii, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Intrinsic Acinetobacter -derived cephalosporinases (ADCs) in Acinetobacter baumannii are AmpC-type β-lactamases that confer resistance to β-lactam agents, typically through insertion sequence (IS) element-driven overexpression. However, the contribution of ADCs to resistance against advanced β-lactam agents has not been systematically investigated. Given the increasing clinical use of these agents, including cefiderocol, we analyzed the diversity and function of ADC variants in a global collection of carbapenem-resistant A. baumannii (CRAb) isolates. We identified 52 distinct ADC variants in a collection of 428 CRAb clinical isolates from the United States. Among these, variants carrying both a valine substitution at position 292 in the R2 loop and an alanine duplication (ADUP) in the Ω loop consistently conferred stable resistance to cefiderocol. Biochemical and crystallographic analyses demonstrated that ADC-227, which harbors a V292W substitution with an ADUP at position 218a in the Ω loop, exhibits enhanced catalytic efficiencies for ceftazidime and cefiderocol and moderately reduced inhibition by avibactam, leading to resistance not only to cefiderocol but also to ceftazidime–avibactam. Structural studies revealed conformational flexibility of the R2 loop, allowing dynamic accommodation of substrates. Collectively, the findings identify Val292, in combination with an ADUP in the Ω loop, as a mutational “hot spot” for ADCs evolution that may undermine the efficacy of newer β-lactams, including cefiderocol. These results underscore the need for ongoing molecular surveillance of A. baumannii isolates to detect and track the emergence of such variants in clinical settings. IMPORTANCE Carbapenem-resistant Acinetobacter baumannii (CRAb) has been designated as a critical priority pathogen by the World Health Organization (WHO). Cefiderocol has been introduced as a novel therapy against CRAb; however, recent clinical data highlight concerning treatment failures and excess mortality. Understanding resistance mechanisms is therefore essential to preserve the clinical utility of this agent. This study addresses a critical knowledge gap by investigating the role of intrinsic Acinetobacter -derived cephalosporinases (ADCs), which are ubiquitous in A. baumannii and diverse in sequence. By defining specific mutational patterns that endanger cefiderocol activity, this work highlights how chromosomally encoded enzymes can evolve to erode the effectiveness of newer β-lactams such as cefiderocol. These insights underscore the importance of integrating molecular surveillance into clinical practice and antimicrobial stewardship to ensure timely detection of emerging resistance in clinical A. baumannii isolates, ultimately informing treatment strategies and guiding future drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Japan.
- Center for Innovative Antimicrobial Therapy, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
- Center for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA.
- Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
- ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
ORCID-Profile: Akito Kawai, Ryan K Shields, Cesar A Arias, Robin Patel, Robert A Bonomo, David van Duin, Yohei Doi
Förderung
- NIH HHS
- National Institutes of Health
- Japan Society for the Promotion of Science
Zitieren
APA
Kawai, A., McElheny, C. L., Shields, R. K., Arias, C. A., Paterson, D. L., Patel, R., Bonomo, R. A., Fowler, V. G., van Duin, D., & Doi, Y. (2026). A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol. mBio. https://doi.org/10.1128/mbio.03518-25
Vancouver
Kawai A, McElheny CL, Shields RK, Arias CA, Paterson DL, Patel R, et al. A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol. mBio. 2026. doi:10.1128/mbio.03518-25
BibTeX
@article{Kawai2026,
author = {Kawai, Akito and McElheny, Christi L and Shields, Ryan K and Arias, Cesar A and Paterson, David L and Patel, Robin and Bonomo, Robert A and Fowler, Vance G and van Duin, David and Doi, Yohei},
title = {A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol},
journal = {mBio},
year = {2026},
doi = {10.1128/mbio.03518-25}
}
EUVIMED